Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533751 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study, sponsored by AnaptysBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
NCT03533751: Completed Phase 2 study, sponsored by AnaptysBio.
NCT03533751 is a Phase 2 study that has completed, run by AnaptysBio. The registered enrollment target is 302 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (127% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03533751, a Phase 2 study, has completed, sponsored by AnaptysBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
Primary Outcome
EASI measures the extent and severity of atopic eczema based on assessments of 4 body regions: head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected and the severity (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for symptoms such as redness (erythema), thickness (induration, papulation, and edema), scratching (excoriation), and lichenification (lined skin) are assessed. Total score is calculated by summing the EASI scores of 6 sympto
Interventions
- DRUG Placebo
- BIOLOGICAL Etokimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2019-12-03 |
| Phase | Phase 2 |
What the finished NCT03533751 record still lists
NCT03533751 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (127% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03533751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03533751 about?
NCT03533751 is a clinical study titled "Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis". This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
What is the current status of trial NCT03533751?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2018-06-19. Estimated completion is 2019-12-03.
What interventions are being tested in trial NCT03533751?
The interventions under investigation include: Placebo (DRUG), Etokimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03533751?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03533751's enrollment target sits among peer trials
302 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI